BioArctic AB's (publ) (Nasdaq Stockholm: BIOA-B) partner Eisai announced today the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly ...

The Alzheimer's Association welcomes today's U.S. Food and Drug Administration (FDA) action to approve weekly subcutaneous maintenance dosing of Leqembi® (lecanemab, Eisai/Biogen) for early ...

Aiming to deliver blockbuster sales of its Alzheimer’s disease-fighting antibody Leqembi in its 2027 fiscal year, Eisai has cleared a key regulatory hurdle in its quest to grow the medicine's reach | ...

The US Food and Drug Administration (FDA) on Friday approved a subcutaneous (SC) formulation of Biogen and Eisai’s Alzheimer’s disease treatment Leqembi (lecanemab), branded as Leqembi Iqlik, for ...

Tokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly ...

OptumRx, a UnitedHealth subsidiary, is tracking three new drugs this year: Brensocatib: An oral treatment for noncystic fibrosis bronchiectasis which gained FDA approval Aug. 12. It is the first ...

The researchers used insulin as a model because it’s a highly sought-after and expensive drug with lots of well-established ...

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat ...

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless ...